esafacts.org

Several independent patient advocacy organizations and consumer groups have submitted letters to the FDA for its March 13 meeting of the Oncologic Drugs Advisory Committee to consider additional issues of risk and benefit in the use of ESAs to treat chemotherapy-induced anemia. Reading these letters provides useful insight into the issues of importance to patients and also some good ideas to consider going forward.

C3 Colorectal Cancer Coalition submitted the letter you can read here: http://www.fightcolorectalcancer.org/news/C3%20ODAC%20Comments%20final.pdf. For additional information on issues related to colorectal cancer see their excellent website here: www.FightColorectalCancer.org.

Breast Cancer Action submitted this letter to the FDA: http://bcation.org/index.php?page=fda-letter-february-27-2008-2. They also have a website that is an excellent source of information and perspective: http://www.bcaction.org/.

We will add links to additional letters as we receive permission from their authors. Stay tuned. . .

This entry was posted on Sunday, March 9th, 2008 at 6:26 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.